f Advances in Cancer Therapeutics and Genomics for Improved Patient Outcomes

References

1. PassiI. SalwanS. KumarB. US-FDA approved drugs in 2020 and 2021, a review.Mini Rev. Med. Chem.202323121273129710.2174/138955752366622120810453036503454
   [Google Scholar]
2. LuD.Y. LuT.R. Antimetastatic drugs, pharmacologic challenge and opportunity.Curr. Drug Ther.202520216917910.2174/0115748855284405231212051251
   [Google Scholar]
3. GerstbergerS. JiangQ. GaneshK. Metastasis.Cell202318681564157910.1016/j.cell.2023.03.00337059065
   [Google Scholar]
4. LuD.Y. XuB. LuT.R. Anticancer drug development, evaluative architecture.Lett. Drug Des. Discov.202421583684610.2174/1570180819666220610102444
   [Google Scholar]
5. LuD.Y. LuT.R. Anticancer drug development, pharmaceutical progress.Curr. Cell Sci.20251610.2174/0127726215312620241029102421
   [Google Scholar]
6. WangD. LiuB. ZhangZ. Accelerating the understanding of cancer biology through the lens of genomics.Cell202318681755177110.1016/j.cell.2023.02.01537059071
   [Google Scholar]
7. ZhongL. ZhaoZ. ZhangX. Genetic differences between primary and metastatic cancer: A pan-cancer whole-genome comparison study.Signal Transduct. Target. Ther.20238136310.1038/s41392‑023‑01596‑037770470
   [Google Scholar]
8. BirkbakN.J. McGranahanN. Cancer genome evolutionary trajectories in metastasis.Cancer Cell202037181910.1016/j.ccell.2019.12.00431935374
   [Google Scholar]
9. LuD.Y. Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics.UKWoodhead Publishing, Elsevier2014
   [Google Scholar]
10. RultenS.L. GroseR.P. GatzS.A. JonesJ.L. CameronA.J.M. The future of precision oncology.Int. J. Mol. Sci.202324161261310.3390/ijms24161261337628794
    [Google Scholar]
11. GadadeD.D. JhaH. KumarC. KhanF. Unlocking the power of precision medicine: Exploring the role of biomarkers in cancer management.Future J. Pharm. Sci.2024101510.1186/s43094‑023‑00573‑2
    [Google Scholar]
12. LiR. KumarA. ChenJ.H. How chatbots and large language model artificial intelligence systems will reshape modern medicine: Fountain of creativity or pandoras box?JAMA Intern. Med.2023183659659710.1001/jamainternmed.2023.183537115531
    [Google Scholar]
13. CariniC. SeyhanA.A. Tribulations and future opportunities for artificial intelligence in precision medicine.J. Transl. Med.202422141110.1186/s12967‑024‑05067‑038702711
    [Google Scholar]
14. NaqaE.I. KarolakA. LuoY. FolioL. TarhiniA.A. RollisonD. ParodiK. Translation of AI into oncology clinical practice.Oncogene202342423089309710.1038/s41388‑023‑02826‑z37684407
    [Google Scholar]
15. SharmaP. GoswamiS. RaychaudhuriD. SiddiquiB.A. SinghP. NagarajanA. LiuJ. SubudhiS.K. PoonC. GantK.L. HerbrichS.M. AnandhanS. IslamS. AmitM. AnandappaG. AllisonJ.P. Immune checkpoint therapy—current perspectives and future directions.Cell202318681652166910.1016/j.cell.2023.03.00637059068
    [Google Scholar]
16. SunT. SinghS. WangH.C. LeeJ. DolatshadH. CheongP.L. HiggsD.R. BoultwoodJ. PellagattiA. Identification of new candidate drugs in myelodysplastic syndromes with splicing factor mutations by transcriptional profiling and connectivity map analysis.Br. J. Haematol.2025bjh.2002610.1111/bjh.2002639988885
    [Google Scholar]